Combined radiosensitizer infusion and irradiation of osteogenic sarcomas

Journal Article · Wed Oct 01 04:00:00 EDT 1975 · Radiology, v. 117, no. 1, pp. 211-214

OSTI ID:4173508

Goffinet, D R; Kaplan, H S; Donaldson, S S; Bagshaw, M A; Wilbur, J R

Three children with osteogenic sarcomas which were either unresectable or whose parents refused permission to amputate were treated with combined intra- arterial 5'bromodeoxyuridine (BUdR) infusion and high-dose-per-fraction megavoltage irradiation to the primary site. Pulsed, 48-hour BUdR infusions were performed prior to each 600-rad radiation therapy fraction, with a total radiation dose to the primary site of 4,200 to 4,800 rads in five weeks. Local control was obtained in all 3 children. One child is alive two years after treatment, another died with metastatic disease, and the third patient who received radiotherapy to the lungs for pulmonary metastases is without evidence of disease one year later. (auth)

• Research Organization: Stanford Univ., California
• NSA Number: NSA-33-000913
• OSTI ID: 4173508
• Journal Information: Radiology, v. 117, no. 1, pp. 211-214, Journal Name: Radiology, v. 117, no. 1, pp. 211-214; ISSN RADLA
• Country of Publication: United States
• Language: English

Related Subjects

*BUDR-- RADIOSENSITIVITY EFFECTS
*OSTEOSARCOMAS-- RADIOTHERAPY
560151* --Biomedical Sciences
Applied Studies--Radiation Effects--Radiation Effects on Animals--Man
CHILDREN
DOSE-RESPONSE RELATIONSHIPS
INJECTION
N48510* --Life Sciences--Radiation Effects on Animals--Man
RADIATION DOSES
RADIOSENSITIZERS
RESPONSE MODIFYING FACTORS